The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.


Journal

Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 08 04 2019
accepted: 06 12 2019
pubmed: 25 12 2019
medline: 30 1 2020
entrez: 25 12 2019
Statut: ppublish

Résumé

The International Prognostic Score (IPS) is the most commonly used risk stratification tool for patients with advanced Hodgkin lymphoma (HL). It incorporates seven clinical parameters independently associated with a poorer outcome: male sex, age, stage IV, hemoglobin level, white blood cell and lymphocyte counts, and albumin level. Since the development of the IPS, there have been significant advances in therapy and supportive care. Recent studies suggest that the IPS is less discriminating due to improved outcomes with ABVD therapy. The aim of the present study was to asses if classic prognostic factors maintain their prognostic meaning at the time of response-adapted treatment based on interim PET scans. We evaluated the prognostic significance of IPS in the 520 advanced stage HL patients enrolled in the PET-guided, HD0801 trial in which PET2-positive patients underwent a more intense treatment with an early stem-cell transplantation after 2 cycles of ABVD. We observed that in these patients, the IPS completely loses its prognostic value together with all the single parameters that contribute to the IPS. Furthermore, neutrophils, monocytes, lymphocytes, and the ratio among them also no longer had any predictive value. We believe that the substantial improvement in survival outcomes in PET2-positive patients treated with early autologous transplantation could explain the complete disappearance of the residual prognostic significance of the IPS.

Identifiants

pubmed: 31872362
doi: 10.1007/s00277-019-03893-7
pii: 10.1007/s00277-019-03893-7
pmc: PMC6976582
doi:

Substances chimiques

Bleomycin 11056-06-7
Vinblastine 5V9KLZ54CY
Dacarbazine 7GR28W0FJI
Doxorubicin 80168379AG

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

277-282

Commentaires et corrections

Type : ErratumIn

Références

J Clin Oncol. 2016 Apr 20;34(12):1376-85
pubmed: 26884559
J Clin Oncol. 2018 Feb 10;36(5):454-462
pubmed: 29360414
J Clin Oncol. 2012 Sep 20;30(27):3383-8
pubmed: 22869887
Mayo Clin Proc. 2015 Jun;90(6):756-64
pubmed: 26046410
Br J Haematol. 2015 Nov;171(4):530-8
pubmed: 26343802
Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43
pubmed: 24811577
N Engl J Med. 1998 Nov 19;339(21):1506-14
pubmed: 9819449
N Engl J Med. 2016 Jun 23;374(25):2419-29
pubmed: 27332902
Blood. 2018 Mar 29;131(13):1456-1463
pubmed: 29437590
Lancet Haematol. 2016 Oct;3(10):e467-e479
pubmed: 27692305
J Clin Oncol. 2013 Feb 20;31(6):684-91
pubmed: 23182987
Ann Hematol. 2018 Jun;97(6):1009-1018
pubmed: 29442162
Hematol Oncol. 2017 Dec;35(4):561-566
pubmed: 27791277
J Clin Oncol. 2013 Feb 20;31(6):692-700
pubmed: 23182984
J Clin Oncol. 2016 Jun 10;34(17):2020-7
pubmed: 27069074
N Engl J Med. 2010 Mar 11;362(10):875-85
pubmed: 20220182

Auteurs

Alessia Bari (A)

UO Terapie Mirate in Oncoematologia ed Osteoncologia, Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Universita' di Modena e Reggio Emilia, Modena, Italy.

Raffaella Marcheselli (R)

Fondazione Italiana Linfomi, Onlus, Alessandria, Italy.

Stefano Sacchi (S)

UO Terapie Mirate in Oncoematologia ed Osteoncologia, Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Universita' di Modena e Reggio Emilia, Modena, Italy. stefano.sacchi@unimore.it.

Alessandro Re (A)

SC Ematologia ASST Spedali Civili, Brescia, Italy.

Chiara Pagani (C)

SC Ematologia ASST Spedali Civili, Brescia, Italy.

Alessandra Tucci (A)

SC Ematologia ASST Spedali Civili, Brescia, Italy.

Barbara Botto (B)

Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin, Italy.

Umberto Vitolo (U)

Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin, Italy.

Anna Lia Molinari (AL)

Unità Operativa di Ematologia, Ospedale degli Infermi di Rimini, Rimini, Italy.

Benedetta Puccini (B)

SOD Ematologia AOU Careggi, Florence, Italy.

Alessandro Pulsoni (A)

Dipartimento di Biotecnologie Cellulari ed Ematologia, Sapienza Università di Roma, Rome, Italy.

Armando Santoro (A)

Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, via Manzoni 56, 20089, Rozzano, Milan, Italy.
Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele - Milan, Italy.

Monica Tani (M)

U.O.C di Ematologia Ospedale Santa Maria delle Croci, Ravenna, Italy.

Luca Nassi (L)

Department of Translational Medicine, Università del Piemonte Orientale Amedeo Avogadro, Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100, Novara, Italy.

Erika Meli (E)

Ematologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Vincenzo Pavone (V)

A.O. C. Panico-U.O.C Ematologia e Trapianto, Tricase, Lecce, Italy.

Maurizio Bonfichi (M)

Div. di Ematologia, IRCCS Policlinico S. Matteo di Pavia, Pavia, Italy.

Andrea Evangelista (A)

Unit of Clinical Epidemiology, AOU Citta' della Salute e della Scienza di Torino and CPO Piemonte, Turin, Italy.

Daniela Gioia (D)

Fondazione Italiana Linfomi, Onlus, Alessandria, Italy.

Alessandro Levis (A)

Fondazione Italiana Linfomi, Onlus, Alessandria, Italy.

Pierluigi Zinzani (P)

Policlinico S.Orsola-Malpighi, Istituto di Ematologia "Seragnoli", Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH